Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

Patients either got a weekly 2.4 milligram dose of semaglutide, the active ingredient in Ozempic and Wegovy, or a placebo, for 72 weeks. The trial found ... a very promising step forward in ...

A major clinical trial reveals Wegovy a popular weight loss drug also treats serious liver disease MASH—reducing liver inflammation and scarring in most patients ...

Novo Nordisk (NYSE:NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the company’s New Drug Application for an oral version of Wegovy. If approved, the pill ...

A late-stage clinical study showed that this weight loss drug helped 2 out of 3 people with the life-threatening liver ...